In this issue Domènech et al. [
] investigated postoperative mortality after surgery for patients with inflammatory bowel disease (IBD) at the population level in Catalonia, Spain over 10 years (2007–2016). Hence, those data reflect contemporary care and include the liberal use of biological therapy. A multidisciplinary approach remains a mainstay of therapy in IBD. Surgical outcomes matter, as nearly every second patient with Crohn's disease (CD) requires surgical care, respectively every tenth patient with ulcerative colitis (UC) [
- Guasch M.
- Domènech E.
- Vela E.
- et al.
Postoperative mortality after surgery for inflammatory bowel disease in the era of biological agents: a population-based study in Southern Europe.
Dig Liv Dis. 2020; https://doi.org/10.1016/j.dld.2020.09.026
- Torres J.
- Bonovas S.
- Doherty G.
- et al.
ECCO guidelines on therapeutics in crohn's disease: medical treatment.
J Crohns Colitis. 2020; 14: 4-22
, in spite of the efficacy and availability of modern medical therapy. In this context, postoperative in-hospital and 30-day mortality rates represent important and objective parameters to evaluate and compare the quality of care delivered in centres caring for IBD patients.
- Adamina M.
- Bonovas S.
- Raine T.
- et al.
Ecco guidelines on therapeutics in crohn's disease: surgical treatment.
J Crohn's Colitis. 2020; 14: 155-168
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Digestive and Liver Disease
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Postoperative mortality after surgery for inflammatory bowel disease in the era of biological agents: a population-based study in Southern Europe.Dig Liv Dis. 2020; https://doi.org/10.1016/j.dld.2020.09.026
- ECCO guidelines on therapeutics in crohn's disease: medical treatment.J Crohns Colitis. 2020; 14: 4-22
- Ecco guidelines on therapeutics in crohn's disease: surgical treatment.J Crohn's Colitis. 2020; 14: 155-168
- A new method of classifying prognostic comorbidity in longitudinal studies: development and validation.J Chronic Dis. 1987; 40: 373-383
- Thirty-day mortality after elective and emergency total colectomy in Danish patients with inflammatory bowel disease: a population-based nationwide cohort study.BMJ Open. 2012; 2e000823
- Mortality after total colectomy in 3084 patients with inflammatory bowel disease: a population-based cohort study.Aliment Pharmacol Ther. 2014; 40: 280-287
- Increased postoperative mortality and complications among elderly patients with inflammatory bowel diseases: an analysis of the national surgical quality improvement.Program Cohort Clin Gastroenterol Hepatol. 2016; 14: 1274-1281
- Tumor necrosis factor alpha inhibitors did not influence postoperative morbidity after elective surgical resections in Crohn's disease.Dig Dis Sci. 2017; 62: 456-464
- Preoperative risk evaluation of postoperative morbidity in IBD patients–impact of the POSSUM score.Int J Colorectal Dis. 2011; 26: 783-792
- Perioperative dietary therapy in inflammatory bowel disease.J Crohns Colitis. 2020 21; 14: 431-444
- Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy.Am J Gastroenterol. 2004; 99: 878-883
- Preoperative use of anti-TNF therapy and postoperative complications in inflammatory bowel diseases: a meta-analysis.J Crohns Colitis. 2013; 7: 853-867
- Meta-analysis: peri-operative anti-TNFα treatment and post-operative complications in patients with inflammatory bowel disease.Aliment Pharmacol Ther. 2013; 37: 1057-1064
- The impact of preoperative steroid use on short-term outcomes following surgery for inflammatory bowel disease.J Crohns Colitis. 2014; 8: 1661-1667
- Biologics and 30-day postoperative complications after abdominal operations for Crohn's disease: are there differences in the safety profiles?.Dis Colon Rectum. 2019; 62: 1352-1362
- Postoperative mortality after nonelective surgery for inflammatory bowel disease patients in the era of biologics.Ann Surg. 2019; 269: 686-691
- Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis.Gastroenterology. 2008; 134: 680-687https://doi.org/10.1053/j.gastro.2008.01.004
- Trends in the surgical treatment of ulcerative colitis over time: increased mortality and centralization of care.World J Surg. 2011; 35: 671-676https://doi.org/10.1007/s00268-010-0910-9
Published online: November 11, 2020
Accepted: October 15, 2020
Received: October 11, 2020
Commentary on the paper DLD-20–1155R1 (Guasch et al.):
Postoperative mortality after surgery for inflammatory bowel disease in the era of biological agents: A population-based study in Southern Europe.
© 2020 Editrice Gastroenterologica Italiana S.r.l. Published by Elsevier Ltd. All rights reserved.
ScienceDirectAccess this article on ScienceDirect
- Postoperative mortality after surgery for inflammatory bowel disease in the era of biological agents: A population-based study in Southern EuropeDigestive and Liver DiseaseVol. 53Issue 1